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Background: Subcutaneous immunoglobulin G (SCIG) may be a better option than intravenous immuno-
globulin G (IVIG) for patients with primary immunodeficiencies (PID) due to reduced systemic and serious
adverse reactions and easier administration. The Infusione Bimensile di Immunoglobuline Sottocute (IBIS)
study investigated the effects of Hizentra, a 20%-concentrated SCIG, administered biweekly in patients with
PID. This subanalysis aimed to evaluate clinical and laboratory outcomes in the IBIS pediatric subcohort.
Methods: Thirteen children with PID were observed for 12 months retrospectively (with previous IVIG/SCIG)
and prospectively with biweekly Hizentra.
Results: Mean – standard deviation serum IG levels during the retrospective (833.8 – 175.7 mg/dL) and the
prospective (842.0 – 188.0 mg/dL) phases were comparable; there were also no differences in the number of
infections.
Conclusions: Biweekly Hizentra is a noninferior option with respect to previous IVIG/SCIG-based treatment.
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Introduction
Primary immunodeficiencies (PID) are a heteroge-neous group of *330 rare, serious, and chronic disorders
of the immune system.1–3 Many patients with primary anti-
body deficiency (PAD) that requires replacement therapy
have switched from the traditional intravenous immuno-
globulin G (IVIG) therapy to subcutaneous immunoglobulin
G (SCIG)4–6 due to systemic and serious adverse reactions7–9
with the former, and ease of administration and patient
compliance with the latter. Hizentra (CSL Behring, King of
Prussia, PA) is a 20%-concentrated, L-proline-stabilized
human SCIG approved by the U.S. Food and Drug Admin-
istration (FDA) and the European Medical Agency for the
treatment of PAD in adults and children.10,11 The ‘‘Infusione
Bimensile di Immunoglobuline Sottocute’’ (IBIS), translated
to biweekly infusion of SCIG, study was a prospective
clinical study that aimed to investigate the clinical and lab-
oratory parameters of patients with PID receiving biweekly
(ie, once every 2 weeks) Hizentra, at double the weekly dose.
Results in the overall population (2–56 years of age) dem-
onstrated that serum levels of immunoglobulin G (IgG)
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achieved during the prospective phase of the study with
SCIG administered biweekly were similar to those deter-
mined during the retrospective phase with once-weekly
SCIG, despite a slight reduction in the monthly dose.12 In
this subanalysis, clinical and laboratory outcomes of the
pediatric population of the IBIS study were evaluated.
Methods
Study design
The full methods of the multicenter, observational IBIS
study have been published previously.12 In brief, clinical
data were collected for each patient over a 24-month period,
which included 12 months each of retrospective and pro-
spective observations (Fig. 1). The current subanalysis of
IBIS examined outcomes in the subcohort of pediatric pa-
tients enrolled in the study.
The study was approved by the Comitato Etico Area
Vasta Centro, Azienda Ospedaliera Universitaria Careggi,
Firenze and the Ethics Committees of each study center and
was conducted in accordance with the Declaration of Hel-
sinki and the current regulations for observational studies.
All patients provided written informed consent before any
evaluations or procedures were conducted.
Patients
Patients were included in the study if they were 1–70
years of age with PID, who required IgG replacement
therapy at a dose that the investigator considered stable and
protective against most infections, undergoing treatment
with IgG (IVIG or SCIG) for ‡12 months, with a switch to
20% SCIG ‡3 months before enrollment. Patients who
changed to administration of SCIG once every 2 weeks upon
enrollment could also be included.
Minimum retrospective data for the 12 months preceding
enrollment included one or more measurement of minimum
plasma IgG concentration representative of the mean value
during the period, details of previous IVIG/SCIG therapy
(monthly doses, frequency of infusions, number of infusion
sites for each session, infusion speed, and number of pumps
used for SCIG), number and type of serious bacterial in-
fections (SBI), such as pneumonia, bacteremia/septicemia,
osteomyelitis/septic arthritis, meningitis, visceral abscess,
other infections, and number of hospitalizations for PID-
related illness.
Main exclusion criteria were treatment with IVIG within
3 months before the enrollment visit, protein-losing illnesses
(eg, lymphangiectasia, nephrosis, protein-losing enteropa-
thy) or solid tumors/hematological neoplasms at enrollment
or during the retrospective phase of the study, ongoing
treatment with systemic corticosteroids, immunosuppressive
drugs, plasma, or other blood derivatives; positivity for
HIV-1, HIV-2, hepatitis C, or hepatitis B markers; preg-
nancy, or participation in clinical trials of investigational
agents; or receiving any other medicinal product that could
interfere with the IgG replacement therapy.
Concomitant or prior therapies for comorbidities related
to PID or other pathologies were allowed during the study
period.
Treatment
The decision to treat patients with 20% SCIG was based
on the judgment of patients’ treating physician in accor-
dance with normal clinical practice.
During the prospective phase of the study, all patients
received biweekly (every 14 – 2 days) Hizentra 20% SCIG.
Patients or caregivers received training on drug administra-
tion from their nurses or treating physician in the hospital.
SCIG therapy was administered at home using pumps for
subcutaneous drug infusion (Crono S-PID, Canè S.r.l., Italy).
Endpoints
A database extraction was performed, before database
lock, allowing exploratory preliminary analyses of the pri-
mary objectives in 13 pediatric patients (ages 2–16). In this
subcohort of patients, age, sex, type of PID, serum IgG
trough levels, number of SBI and of other infections, and
number of days with antibiotic therapy were examined.
FIG. 1. Design of the IBIS












Age at enrollment, years
Median (IQR) 13 (9–14)
Range 2–16
Age at diagnosis, years
Median (IQR) 3 (2–6)
Range 1–13





CVID, common variable immunodeficiency; DGS, DiGeorge
syndrome; IgG, immunoglobulin G; IgGSCD, IgG subclass defi-
ciency; IQR, interquartile range; n, number; XLA, X-linked
agammaglobulinemia.
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During the prospective phase, patients were followed up at
3, 6, and 12 months, and data were collected using electronic
case report forms.
Statistical analyses
Evaluable patients were those receiving IgG and with data
available for both the retrospective and prospective periods.
Parameters of interest were summarized, in the entire sub-
cohort and for each study phase, using descriptive statistics
[mean, standard deviation (SD), 25th and 75th percentiles,
median, minimum, and maximum].
Results
Patients
A total of 13 pediatric patients were enrolled from 5
centers in Italy. Patient demographics and clinical charac-
teristics at enrollment are shown in Table 1; the same data,
separated by each patient, are listed in Table 2. The majority
of patients were male (N = 10, 76.9%) and the most frequent
PID diagnosis was common variable immunodeficiency
(N = 8, 61.5%). In this subcohort, median [interquartile range
(IQR)] age at enrollment was 13 (9–14) years, whereas the
median (IQR) age at diagnosis was 3 (2–6) years. All patients
were previously on substitution therapy with SCIG and only 3
patients received IVIG previously and only for a short time.
Serum IgG levels
The mean serum IgG trough levels remained stable with
SCIG administered biweekly (Fig. 2). During the retrospective
and prospective phases of the study, mean – SD serum IgG
levels were similar, at 833.8 – 175.7 and 842.0 – 188.0 mg/dL,
respectively (Fig. 3A).
In the prospective analysis, all serum IgG trough levels
collected during the 12-month-long follow-up were in-
cluded, and not only those referred to the 3-, 6-, and 12-
month scheduled follow-up visits.
Number of serious and other infections
No significant differences were observed between the 2
study phases either in the number of SBI or in the number of
other infections. Two episodes of SBI were reported (pneu-
monia during the retrospective period and visceral abscess in
the prospective period), with a mean – SD annualized rate of
0.08 – 0.28 in both periods.
During the retrospective period, 29 episodes of nonserious
infections (Fig. 3B) were recorded, with a mean annualized
rate of 2.23 – 2.62 (Fig. 3C). Of the 13 patients, 10 (77%)
experienced one or more infections. The most frequent type
of infection was bronchitis (N = 9, 31.0%). During the pro-
spective phase, there were 35 cases of nonserious infections
(Fig. 3B), with a mean annualized rate of 2.69 – 3.64 (Fig. 3C).
Nine out of the total 13 patients (69%) experienced one or
more infections. Pharyngitis was the most common type of
infection (N = 9, 25.7%).
Table 2. List of Demographics and Clinical











02-01 CVID M 8 5
02-02 XLA M 13 1
02-03 XLA M 2 1
05-02 CVID M 16 13
06-01 CVID F 15 1
06-02 CVID M 14 6
06-03 DGS M 15 2
06-04 IgGSCD M 14 12
06-06 CVID M 7 4
06-08 CVID F 14 8
07-01 XLA M 13 3
07-02 CVID F 10 2
08-01 CVID M 9 3
PID, primary immunodeficiency.
FIG. 2. Serum IgG trough levels during the retrospective and prospective phases when patients received subcutaneous
immunoglobulins. FPFV, first patient first visit; IgG, immunoglobulin G; LPLV, last patient last visit.
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Duration of antibiotic therapy
There was no significant difference between the 2 study
phases in the duration of antibiotic therapy. The mean – SD
duration of antibiotic therapy was 14.7 – 15.7 and 13.7 – 21.8
days per patient during the retrospective and prospective
phases, respectively (Fig. 3D).
Discussion
This subanalysis of the IBIS study investigated the effect
of biweekly SCIG on serum IgG levels and its clinical ef-
ficacy in pediatric patients with PID. Compared with the
previous weekly SCIG regimen, 20% SCIG administered
biweekly at double the weekly dose maintained similar
FIG. 3. Comparison of (A) IgG levels, (B) number of infections, (C) rate of infections, (D) antibiotic therapy.
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serum IgG levels and similar rates of serious bacterial and
nonserious infections in pediatric patients with PID.
Biweekly administration of 20% SCIG maintained pre-
infusion trough levels of IgG above the recommended level
of 500 mg/dL13 throughout the prospective study period.
These results are consistent with published literature and data
generated by pharmacometric modeling and simulations. As
there are no specific studies of biweekly SCIG published
specifically in children, it is difficult to perform direct com-
parisons. Nevertheless, the serum IgG levels observed in this
study were similar to those reported in a study of weekly
SCIG in 23 pediatric patients with PID.14 In another study, 12
adults with PID had constantly high serum IgG levels without
major variations over 24 weeks of treatment with 16% SCIG
infusions every other week.15
There was no increase in the number of days of antibiotic
therapy for infections during the prospective phase of the
study compared with the retrospective phase of the study. The
mean annualized rate for SBI was 0.08 in both periods and
was comparable to a previously published study with Hizentra
treatment16; this rate is significantly less than the threshold of
1 SBI, as recommended by the U.S. FDA required to show
IgG therapy efficacy.17 Accordingly, the proportion of patients
with at least 1 infection was 77% during the retrospective
period and 69% in the prospective period, which was con-
sistent with the published literature (78.3%).16 Since the pe-
diatric cohort was observed for 12 consecutive months, bias
related to the seasonality of infections is mitigated.
The IBIS study did not compare the rate of adverse drug
reactions (ADRs) between IVIG and SCIG. However, in our
experience, systemic ADR—such as fever, headache, and
flu-like symptoms—are less common during biweekly ad-
ministration of Hizentra compared with IVIG treatment. As
expected, transient and mild, local infusion site reactions
were observed.
In our opinion, a further advantage of biweekly SCIG
therapy is on the psychological aspect of the patient related
to the treatment of these chronic diseases. In fact, biweekly
administration at home reduces the number of infusion
sessions per month so that less time is dedicated to therapy
allowing more time for other playful activities that are so
fundamental in childhood without the need for periodic
hospitalization required by IVIG.
The main limitation of this subanalysis was the retro-
spective design, in which missing or incomplete data, as
well as recall bias, could have affected the primary analysis.
To limit this potential source of distortion, a minimum ret-
rospective set of required data was defined. Furthermore, the
limited sample size affected the statistical power of study
endpoints and rare adverse events may have been unde-
tected. This may be addressed in future studies on a larger
population of patients with PID.
Conclusions
This subanalysis of the IBIS study provided real world
evidence that switching from Hizentra with weekly ad-
ministered to a biweekly regimen, in pediatric patients, did
not compromise serum IgG levels or the rate and severity
of infections and was noninferior with respect to previous
IVIG/SCIG-based treatment. Therefore, biweekly 20%
SCIG Hizentra was an effective option in pediatric patients
with PID.
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